Sign up for our daily briefing
Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.
Stay on top of the latest market trends
Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.
Sports news worthy of your time
Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.
Tech news worthy of your time
Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.
Get the inside stories
Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Want a daily digest of the top Denver news?
Get a daily digest of the most important stories affecting your hometown with Axios Denver
Want a daily digest of the top Des Moines news?
Get a daily digest of the most important stories affecting your hometown with Axios Des Moines
Want a daily digest of the top Twin Cities news?
Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities
Want a daily digest of the top Tampa Bay news?
Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay
Want a daily digest of the top Charlotte news?
Get a daily digest of the most important stories affecting your hometown with Axios Charlotte
Allergan CEO Brent Saunders is interviewed on the floor of the New York Stock Exchange. Photo: Richard Drew / AP
Pharmacies and pharmacy benefit managers are terrified about the prospect of Amazon getting into their business. But pharmaceutical companies are all for it, CNBC reports. "I think the drug distribution channel also should be disrupted with improvements based on technology or efficiency," Allergan CEO Brent Saunders told analysts yesterday, according to CNBC. "It's an area rife with inefficiency and a lot of turf," another pharma CEO said in the report. "It's overly complicated; that's the opportunity."
Between the lines: Drug companies are especially frustrated with pharmacy benefit managers, which function as intermediaries between manufacturers and pharmacies. Pharma companies complain that PBMs mark up their products without disclosing those costs, and cutting into PBMs' slice of the pie is pharma's preferred solution to the controversy over high drug prices.